Use of 68GaGa-PSMA PETCT Imaging to Improve Diagnosis and Monitoring in Patients with Hepatocellular Carcinoma

What this Trial Is About

Researchers are evaluating the use of multiparametric dynamic whole-body 68GaGa-PSMA PETCT imaging in patients newly diagnosed with hepatocellular carcinoma HCC or those with recent suspicion of refractory, residual, or recurrent disease. The study aims to assess how this imaging technique performs diagnostically and to explore kinetic modeling in this patient population. Participants receive a dynamic whole-body 68GaGa-PSMA PETCT scan as the investigational procedure. This involves the administration of 68GaGa-PSMA-11 as a radiation-based imaging agent. The study does not mention multiple treatment groups or comparators and focuses on detailed imaging acquisition and analysis. During the study, participants undergo imaging assessments at baseline and follow-up evaluations over six months to measure diagnostic performance, comfort during the procedure, and compare dynamic versus static imaging approaches. Researchers will collect kinetic parameters and evaluate the imaging results at both lesion and patient levels. The total study involvement includes baseline imaging and follow-up assessments within a six-month period to monitor outcomes and safety.

[68Ga]Ga-PSMA PET/CT in Hepatocellular Carcinoma: Impact of Multiparametric Dynamic Whole-body Imaging and Kinetic Modeling.